Literature DB >> 12433693

Hematopoietic origin of glomerular mesangial cells.

Masahiro Masuya1, Christopher J Drake, Paul A Fleming, Christopher M Reilly, Haiqun Zeng, William D Hill, Angeline Martin-Studdard, David C Hess, Makio Ogawa.   

Abstract

It was recently reported that crude bone marrow cells have the ability to differentiate into glomerular mesangial cells. However, the exact nature of the engrafting cells in the bone marrow was not known. We tested the hypothesis that hematopoietic stem cells are capable of reconstituting the mesangial cells by transplanting a clonal population of cells derived from a single stem cell. We cultured Lin(-), Sca-1(+), c-kit(+), CD34(-) bone marrow cells from transgenic enhanced green fluorescent protein (EGFP) mice (C57BL/6-Ly-5.2 background) individually for 1 week in the presence of interleukin-11 and steel factor. We then transplanted viable clones individually into lethally irradiated C57BL/6-Ly-5.1 mice. Kidneys from 5 recipient mice showing high levels (60%-90%) of multilineage hematopoietic reconstitution were examined 2 to 6 months later, using differential interference contrast and epifluorescence microscopy. EGFP(+) cells with a morphology characteristic of mesangial cells were evident within the glomeruli. Transplantation of 100 noncultured Lin(-), Sca-1(+), c-kit(+), CD34(-) bone marrow cells also generated mesangial cells. Cultured EGFP(+) glomerular cells from recipient mice contracted in response to angiotensin II. EGFP(+) mesangial cells seen in male-to-male transplants revealed only one Y-chromosome. These data demonstrate that a single hematopoietic stem cell is capable of differentiating into glomerular mesangial cells and that the process does not involve cell fusion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433693     DOI: 10.1182/blood-2002-04-1076

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

Review 1.  Recipes for adult stem cell plasticity: fusion cuisine or readymade?

Authors:  M R Alison; R Poulsom; W R Otto; P Vig; M Brittan; N C Direkze; M Lovell; T C Fang; S L Preston; N A Wright
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

Review 2.  Hematopoietic stem cell origin of mesenchymal cells: opportunity for novel therapeutic approaches.

Authors:  Makio Ogawa; Amanda C Larue; Patricia M Watson; Dennis K Watson
Journal:  Int J Hematol       Date:  2010-03-26       Impact factor: 2.490

Review 3.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

Review 4.  Stem cell plasticity: the debate begins to clarify.

Authors:  Alexandros Spyridonidis; Robert Zeiser; Marie Follo; Yannis Metaxas; Jürgen Finke
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

Review 5.  The stem cell continuum: considerations on the heterogeneity and plasticity of marrow stem cells.

Authors:  Peter J Quesenberry; G Dooner; M Dooner; G Colvin
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

Review 6.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 7.  Hematopoietic stem cells are pluripotent and not just "hematopoietic".

Authors:  Makio Ogawa; Amanda C LaRue; Meenal Mehrotra
Journal:  Blood Cells Mol Dis       Date:  2013-02-27       Impact factor: 3.039

Review 8.  Adult stem cell plasticity: will engineered tissues be rejected?

Authors:  Te-Chao Fang; Malcolm R Alison; Nicholas A Wright; Richard Poulsom
Journal:  Int J Exp Pathol       Date:  2004-06       Impact factor: 1.925

Review 9.  Macrophage diversity in renal injury and repair.

Authors:  Sharon D Ricardo; Harry van Goor; Allison A Eddy
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

10.  Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia.

Authors:  Keisuke Shirai; Yasuhiko Sera; William Bulkeley; Meenal Mehrotra; Omar Moussa; Amanda C LaRue; Dennis K Watson; Robert K Stuart; John Lazarchick; Makio Ogawa
Journal:  Exp Hematol       Date:  2009-09-26       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.